糖尿病神經性疼痛市場－全球產業規模、佔有率、趨勢、機會和預測，按神經病變類型、藥物類別、配銷通路、地區和競爭情況細分，2020 年至 2030 年

2024 年全球糖尿病神經性疼痛市場價值為 16.4 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 5.68%。全球糖尿病神經性疼痛市場是更廣泛的醫療保健產業中一個充滿活力且快速發展的產業，其特點是全球糖尿病盛行率不斷上升。例如，2022 年國際糖尿病聯盟報告稱，全球約有 5.37 億 20 至 79 歲的成年人患有糖尿病，佔全球人口的十分之一，凸顯了該疾病在全球範圍內日益加重的負擔。糖尿病神經性疼痛是糖尿病的一種痛苦和衰弱的併發症，影響著相當一部分糖尿病患者。該市場涵蓋廣泛的藥物、醫療設備和治療干預措施，旨在緩解糖尿病神經病變患者所經歷的慢性疼痛和不適。推動全球糖尿病神經性疼痛市場成長的關鍵因素包括糖尿病發生率的上升，特別是在新興經濟體，以及全球人口老化。隨著糖尿病的發生率不斷上升，糖尿病神經病變的盛行率也在上升，這通常會導致神經性疼痛。這反過來又刺激了對有效疼痛管理解決方案的需求並推動了市場創新。例如，根據疾病預防控制中心的數據，美國約有 3,420 萬人（佔總人口的 10.5%）患有糖尿病，包括確診和未確診病例。相當一部分患者未被診斷出來或處於糖尿病前期，凸顯了人們對糖尿病管理和預防日益成長的關注。

主要市場促進因素

糖尿病疫情不斷升級

主要市場挑戰

治療抵抗

主要市場趨勢

以病人為中心的護理

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第 4 章：全球糖尿病神經性疼痛市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依神經病變類型（周邊神經病變、自主神經病變、近端神經病變、局部神經病變）
  • 依藥物類別（抗憂鬱藥、抗驚厥藥、止痛藥）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按神經病變類型
  • 按藥物類別
  • 按配銷通路
  • 按地區

第5章：亞太地區糖尿病神經性疼痛市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按神經病變類型
  • 按藥物類別
  • 按配銷通路
  • 按國家
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 6 章：歐洲糖尿病神經性疼痛市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 7 章：北美糖尿病神經性疼痛市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲糖尿病神經性疼痛市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第9章：中東和非洲糖尿病神經性疼痛市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 12 章：全球糖尿病神經性疼痛市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Eli Lilly and Company
• Grunenthal GmBH
• Collegium Pharmaceutical, Inc.
• Lupin Ltd
• Daiichi Sankyo Inc.
• Azurity Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Endo International plc. (Par Pharmaceutical)
• Johnson & Johnson

第 15 章：策略建議

第16章調查會社について,免責事項

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.

Key Market Drivers

Escalating Diabetes Epidemic

The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.

Key Market Challenges

Treatment Resistance

One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.

Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.

Key Market Trends

Patient-Centered Care

Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.

Key Market Players

Eli Lilly and Company

Grunenthal GmBH

Collegium Pharmaceutical, Inc.

Lupin Ltd

Daiichi Sankyo Inc.

Azurity Pharmaceuticals, Inc.

Novartis AG

Pfizer, Inc.

Endo International plc. (Par Pharmaceutical)

Johnson & Johnson

Report Scope:

In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Neuropathic Pain Market, By Neuropathy Type:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Diabetic Neuropathic Pain Market, By Drug Class:

• Antidepressants
• Anticonvulsants
• Analgesics

Diabetic Neuropathic Pain Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Neuropathic Pain Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.

Available Customizations:

Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Neuropathic Pain Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy)
  • 4.2.2. By Drug Class (Antidepressants, Anticonvulsants, Analgesics)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Neuropathy Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Diabetic Neuropathic Pain Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Neuropathy Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Neuropathic Pain Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Neuropathy Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Diabetic Neuropathic Pain Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Neuropathy Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Diabetic Neuropathic Pain Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Neuropathy Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Diabetic Neuropathic Pain Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Neuropathy Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Diabetic Neuropathic Pain Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Neuropathy Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Distribution Channel

6. Europe Diabetic Neuropathic Pain Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Neuropathy Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Neuropathic Pain Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Neuropathy Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Diabetic Neuropathic Pain Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Neuropathy Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Diabetic Neuropathic Pain Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Neuropathy Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Diabetic Neuropathic Pain Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Neuropathy Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Neuropathic Pain Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Neuropathy Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Distribution Channel

7. North America Diabetic Neuropathic Pain Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Neuropathy Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Neuropathic Pain Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Neuropathy Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Diabetic Neuropathic Pain Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Neuropathy Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Diabetic Neuropathic Pain Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Neuropathy Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel

8. South America Diabetic Neuropathic Pain Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Neuropathy Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Neuropathic Pain Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Neuropathy Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Diabetic Neuropathic Pain Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Neuropathy Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Diabetic Neuropathic Pain Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Neuropathy Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Neuropathy Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Neuropathic Pain Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Neuropathy Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Neuropathic Pain Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Neuropathy Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Diabetic Neuropathic Pain Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Neuropathy Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Diabetic Neuropathic Pain Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Neuropathy Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Neuropathic Pain Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Grunenthal GmBH
• 14.3. Collegium Pharmaceutical, Inc.
• 14.4. Lupin Ltd
• 14.5. Daiichi Sankyo Inc.
• 14.6. Azurity Pharmaceuticals, Inc.
• 14.7. Novartis AG
• 14.8. Pfizer, Inc.
• 14.9. Endo International plc. (Par Pharmaceutical)
• 14.10.Johnson & Johnson

15. Strategic Recommendations

16. About Us & Disclaimer